Pulse Biosciences, Inc. awarded its Chief Technology Officer, Darrin R. Uecker, a grant of restricted stock units (RSUs). The grant represents 100,000 shares of the company's common stock, par value $0.001. The award recognizes Mr. Uecker's continued leadership in product development efforts for the treatment of atrial fibrillation. The RSUs will vest in full on the third anniversary of the grant date, March 23, 2029. The grant is subject to the terms and conditions of the grant award agreement and the company's Amended and Restated 2017 Equity Incentive Plan.